BioHealx

Healx is a clinical-stage biotechnology company that leverages artificial intelligence to accelerate the discovery and development of treatments for rare diseases. The company's proprietary AI platform, Healnet, integrates massive amounts of biomedical data to identify novel drug-disease relationships and predict effective combination therapies. By focusing on drug repurposing and repositioning, Healx aims to significantly reduce the time and cost associated with traditional drug development. The company's lead program is currently in Phase 2 clinical trials for the treatment of Fragile X syndrome, with a growing pipeline targeting various rare neurological and genetic disorders.